MIOS

Across TCGA pan-cancer cohorts, MIOS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIOS data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MIOS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MIOS expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where MIOS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.565	0.251	<.001	99	view →
CCRCC	OS	Median	All	1.000	0.890	.004	16	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIOS–PDAC (OS)

Open the PDAC breakdown →